The Impact of Prodromal Stage Non-Motor Symptoms on Clinical Progression in Parkinson’s Disease

Basit Öğe Kaydı
dc.contributor.authorSay, Bahar
dc.contributor.authorÜnal, Yasemin
dc.contributor.authorAksun, Zerin Özaydın
dc.contributor.authorYılmaz, Rezzak
dc.contributor.authorAkbostancı, Cenk
dc.date.accessioned2025-01-21T16:19:26Z
dc.date.available2025-01-21T16:19:26Z
dc.date.issued2022
dc.departmentKırıkkale Üniversitesi
dc.description.abstractObjectives: Several non-motor symptoms (NMSs) were described in the prodromal Parkinson’s disease (PD). The aim of this study is to investigate the impact of the presence of prodromal NMSs on clinical progression of PD. Materials and Methods: We questioned the presence of NMSs in the prediagnostic stage in patients with PD. Group 1 reported at least one prodromal NMS and Group 2 reported no prodromal NMSs. As recommended by the Movement Disorder Society Task Force, the total likelihood ratios (LRs) of NMSs were calculated and correlated with disease progression. Clinical progression was determined by dividing the Unified Parkinson’s Disease Rating Scale Part III total score by the duration of the disease. Generalized linear model (GzLM) was used to determine associations between clinical progression rate and the predictor variables. Results: Group 1 had 48 patients (24 male, 24 female), and Group 2 had 46 patients (32 male, 14 female). Both groups were similar in terms of demographic and disease characteristics. Depression and constipation (for each symptom, 18 patients and 37.5%) were common in Group 1. The rate of clinical progression was higher in Group 1 than in Group 2 (p=0.037). There was no significant correlation between clinical progression rate and LRs of NMSs in Group 1 (rs=0.10, p=0.49). However, age of the diagnosis was the only significant factor associated with the clinical progression (p=0.69). Conclusion: Prodromal NMSs do not seem to impact the rate of disease progression, which may be explained by the non-dopaminergic and extra nigro-striatal pathway that cause NMSs.
dc.identifier.doi10.4274/atfm.galenos.2021.56578
dc.identifier.endpage68
dc.identifier.issn0365-8104
dc.identifier.issn1307-5608
dc.identifier.issue1
dc.identifier.startpage63
dc.identifier.trdizinid1125249
dc.identifier.urihttps://doi.org/10.4274/atfm.galenos.2021.56578
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1125249
dc.identifier.urihttps://hdl.handle.net/20.500.12587/23082
dc.identifier.volume75
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofAnkara Üniversitesi Tıp Fakültesi Mecmuası
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241229
dc.subjectTıbbi Araştırmalar Deneysel
dc.subjectGenel ve Dahili Tıp
dc.subjectNörolojik Bilimler
dc.titleThe Impact of Prodromal Stage Non-Motor Symptoms on Clinical Progression in Parkinson’s Disease
dc.typeArticle

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu